Children’s Hospital of Philadelphia increased average monthly naloxone, known as Narcan, co-prescribing for patients receiving outpatient opioid prescriptions from 3% to 84.1% through an enterprisewide quality improvement initiative, according to a study published June 16 in The Journal of Pediatrics.
The initiative was implemented between October 2023 and June 2025 in three phases, using an EHR-based automated alert to co-prescribe naloxone along with education for providers, nurses, pharmacists, patients and families.
Here are four things to know:
- In 2023, less than 3% of patients prescribed opioids at discharge from CHOP also received a naloxone prescription. The initiative, part of CHOP’s Empower Program, aimed to increase co-prescribing to at least 80% for eligible patients.
- Nearly 60% of naloxone prescriptions were filled through CHOP pharmacies. The team also partnered with the outpatient pharmacy to monitor out-of-pocket costs, identify financial barriers and expand access to a Pennsylvania state discount program previously available only to adult patients.
- Early feedback showed that perceived stigma and costs were barriers to dispensing, but 81.8% of providers reported that naloxone was easy to prescribe and 86.4% reported high levels of comfort when offering the medication to families.
- Researchers found EHR-based prompts combined with education for providers increased naloxone co-prescribing across the large pediatric health system.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
